7 min
Ep 38. Is risankizumab safe and effective for active psoriatic arthritis? Results from the KEEPsAKE 2 study Talking Rheumatology Research
-
- Medicine
Dr Andrew Östör joins Dr Marwan Bukhari to discuss their article, chosen as the June Editor's Choice article, which evaluates the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or two biologic therapies (Bio-IR) or one or more conventional synthetic DMARDs (csDMARD-IR).
Listen now to hear the findings and what this means for future clinical practice!
You can read this article [https://doi.org/10.1093/rheumatology/keac605] in Rheumatology.
Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.
Dr Andrew Östör joins Dr Marwan Bukhari to discuss their article, chosen as the June Editor's Choice article, which evaluates the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or two biologic therapies (Bio-IR) or one or more conventional synthetic DMARDs (csDMARD-IR).
Listen now to hear the findings and what this means for future clinical practice!
You can read this article [https://doi.org/10.1093/rheumatology/keac605] in Rheumatology.
Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.
7 min